Literature DB >> 9834007

Stability of UC-781, in intestinal mucosal homogenates of the rat, rabbit, and pig.

G Van den Mooter1, G Stas, F Damian, L Naesens, J Balzarini, R Kinget, P Augustijns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9834007     DOI： 10.1023/a:1011985418360

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  10 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 2.  Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections.

Authors:  E De Clercq
Journal:  J Med Chem       Date:  1995-07-07       Impact factor: 7.446

Review 3.  Metabolism of drugs and other xenobiotics in the gut lumen and wall.

Authors:  K F Ilett; L B Tee; P T Reeves; R F Minchin
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

4.  Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus.

Authors:  J Balzarini; W G Brouwer; D C Dao; E M Osika; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 5.  Active secretion and enterocytic drug metabolism barriers to drug absorption.

Authors:  V J Wacher; L Salphati; L Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

6.  Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.

Authors:  J Balzarini; H Pelemans; S Aquaro; C F Perno; M Witvrouw; D Schols; E De Clercq; A Karlsson
Journal:  Mol Pharmacol       Date:  1996-08       Impact factor: 4.436

7.  Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.

Authors:  J B McMahon; R W Buckheit; R J Gulakowski; M J Currens; D T Vistica; R H Shoemaker; S F Stinson; J D Russell; J P Bader; V L Narayanan; R J Schultz; W G Brouwer; E E Felauer; M R Boyd
Journal:  J Pharmacol Exp Ther       Date:  1996-01       Impact factor: 4.030

8.  Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues.

Authors:  I de Waziers; P H Cugnenc; C S Yang; J P Leroux; P H Beaune
Journal:  J Pharmacol Exp Ther       Date:  1990-04       Impact factor: 4.030

9.  Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.

Authors:  R W Buckheit; T L Kinjerski; V Fliakas-Boltz; J D Russell; T L Stup; L A Pallansch; W G Brouwer; D C Dao; W A Harrison; R J Schultz
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).

Authors:  J Balzarini; M J Pérez-Pérez; S Vélazquez; A San-Félix; M J Camarasa; E De Clercq; A Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205
  10 in total
  1 in total

Review 1.  Advances in colonic drug delivery.

Authors:  Abdul W Basit
Journal:  Drugs       Date:  2005       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.